Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|January 26, 2018

Comecar in $12-Million Deal to Equip German Cell Culture Lab

Comecar will provide cell culture equipment for biopharmaceutical company CO.DON AG's new production site in Leipzig, Germany.

Comecer Group, an Italian provider of isolation equipment and systems for the pharmaceutical and nuclear medicines industries, announced on Jan. 18, 2018 that it signed an agreement with CO.DON AG, a German biopharmaceutical company focused on autologous cell therapies, to supply modular isolator and cell culture incubation systems in aseptic environment for CO.DON AG's new production site being built in Leipzig, Germany. The contract is valued at approximately EUR 10 million (US$12 million). Installation and startup of the equipment is expected in the next 10-12 months.

"We are honored to be part of this great project in what is considered the future of medicine. The fact that our patented technology has been selected by CO.DON makes us proud and confirms the considerable commitment undertaken by our company in this rapidly developing sector," said Alessia Zanelli, CEO of Comecer Group, in a company press release.

"We are delighted to have such an experienced partner as Comecer, with its many years of specialist expertise. Together we will perform this challenging task. CO.DON is entering a new dimension: once all the work is finished, the production site will be one of the world's largest and most modern plants for the industrial-scale production of human cells. It will enable us to ensure the supply of the highest quality cell therapy products to our customers in Germany and Europe going forward," added Ralf Jakobs, CEO of CO.DON AG, in the release.

Source: Comecer Group


Related to this article

The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.